JP2016512259A5 - - Google Patents

Download PDF

Info

Publication number
JP2016512259A5
JP2016512259A5 JP2016500760A JP2016500760A JP2016512259A5 JP 2016512259 A5 JP2016512259 A5 JP 2016512259A5 JP 2016500760 A JP2016500760 A JP 2016500760A JP 2016500760 A JP2016500760 A JP 2016500760A JP 2016512259 A5 JP2016512259 A5 JP 2016512259A5
Authority
JP
Japan
Prior art keywords
methyl
chlorophenyl
difluoromethoxy
methoxypyridin
triazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016500760A
Other languages
English (en)
Japanese (ja)
Other versions
JP6282721B2 (ja
JP2016512259A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/021426 external-priority patent/WO2014158998A1/en
Publication of JP2016512259A publication Critical patent/JP2016512259A/ja
Publication of JP2016512259A5 publication Critical patent/JP2016512259A5/ja
Application granted granted Critical
Publication of JP6282721B2 publication Critical patent/JP6282721B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016500760A 2013-03-14 2014-03-06 Pde4阻害剤としての置換ピリジン及びピラジン化合物 Active JP6282721B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361786288P 2013-03-14 2013-03-14
US61/786,288 2013-03-14
PCT/US2014/021426 WO2014158998A1 (en) 2013-03-14 2014-03-06 Substituted pyridine and pyrazine compounds as pde4 inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018009464A Division JP6505878B2 (ja) 2013-03-14 2018-01-24 Pde4阻害剤としての置換ピリジン及びピラジン化合物

Publications (3)

Publication Number Publication Date
JP2016512259A JP2016512259A (ja) 2016-04-25
JP2016512259A5 true JP2016512259A5 (enExample) 2017-04-06
JP6282721B2 JP6282721B2 (ja) 2018-02-21

Family

ID=51530139

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016500760A Active JP6282721B2 (ja) 2013-03-14 2014-03-06 Pde4阻害剤としての置換ピリジン及びピラジン化合物
JP2018009464A Active JP6505878B2 (ja) 2013-03-14 2018-01-24 Pde4阻害剤としての置換ピリジン及びピラジン化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018009464A Active JP6505878B2 (ja) 2013-03-14 2018-01-24 Pde4阻害剤としての置換ピリジン及びピラジン化合物

Country Status (17)

Country Link
US (8) US20160009691A1 (enExample)
EP (2) EP2970212B1 (enExample)
JP (2) JP6282721B2 (enExample)
KR (1) KR102232221B1 (enExample)
CN (2) CN105143207B (enExample)
AU (2) AU2014241430B2 (enExample)
BR (1) BR112015022474B1 (enExample)
CA (1) CA2895209C (enExample)
DK (1) DK3345902T3 (enExample)
ES (1) ES2769181T3 (enExample)
IL (1) IL240804B (enExample)
MX (1) MX370188B (enExample)
NZ (1) NZ711587A (enExample)
RU (1) RU2668073C2 (enExample)
SG (2) SG11201504709PA (enExample)
TW (2) TWI623523B (enExample)
WO (1) WO2014158998A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201504709PA (en) * 2013-03-14 2015-07-30 Dart Neuroscience Llc Substituted pyridine and pyrazine compounds as pde4 inhibitors
WO2018064465A1 (en) * 2016-09-29 2018-04-05 The Regents Of The University Of California Compounds for increasing neural plasticity
EP3773562A1 (en) * 2018-04-05 2021-02-17 Universiteit Hasselt Selective pde4d inhibitors against demyelinating diseases
CN109438434B (zh) * 2018-11-19 2021-05-04 华南农业大学 一种含噁唑环的2-氰基亚氨基噻唑烷类化合物及其制备方法和应用
EP3931189B1 (en) 2019-02-27 2025-12-24 The Regents Of The University Of California Azepino-indoles and other heterocycles for treating brain disorders
CA3130767A1 (en) 2019-02-27 2020-09-03 The Regents Of The University Of California N-substituted indoles and other heterocycles for treating brain disorders
WO2020219615A1 (en) * 2019-04-23 2020-10-29 Tetra Discovery Partners, Inc. 3-hydroxy-2-phenyl-6-(pyrazol-4-ylmethyl)pyridine derivatives as pde4d inhibitors
CN114072143A (zh) * 2019-05-06 2022-02-18 钙医学公司 Crac通道抑制剂的合成
EP3873883B1 (en) * 2019-11-07 2022-12-21 Small Pharma Ltd Method of synthesis
EP4192828A1 (en) 2020-08-04 2023-06-14 Nura Bio, Inc. Substituted pyridine derivatives as sarm1 inhibitors
CN111995585B (zh) * 2020-08-04 2022-01-25 常州大学 嘧啶乙酰胺类化合物及其作为磷酸二酯酶pde2活性抑制剂的应用
WO2022060812A1 (en) 2020-09-16 2022-03-24 Nura Bio, Inc. Substituted pyridine derivatives as sarm1 inhibitors
EP4243813A4 (en) 2020-11-13 2024-07-17 Calcimedica, Inc. IMPROVED SYNTHESIS OF CRAC CHANNEL INHIBITORS
KR20240041987A (ko) 2021-07-28 2024-04-01 누라 바이오, 인크. Sarm1 억제제로서 치환된 피리딘 유도체
CA3239565A1 (en) 2021-12-15 2023-06-22 Delix Therapeutics, Inc. Phenoxy and benzyloxy substituted psychoplastogens and uses thereof
CN116265440B (zh) * 2021-12-16 2024-09-27 贵州大学 一种水杨酮拼接吡啶酮类化合物及其制备方法及应用
EP4562001A1 (en) * 2022-07-27 2025-06-04 Nura Bio, Inc. Substituted pyridine derivatives as sarm1 inhibitors
EP4596554A4 (en) 2022-09-29 2025-12-10 Suzhou Arkbiopharmaceutical Co Ltd Fused AZA Cyclic Compound, its Preparation Process and its Use in Medicine
CN116082254B (zh) * 2022-12-28 2025-04-11 浙江永太科技股份有限公司 一种1-烷基-1,2,4-三氮唑-3-甲醇的制备方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
WO1999031062A1 (en) * 1997-12-17 1999-06-24 Shionogi & Co., Ltd. Novel pyridine compounds
US9931318B2 (en) 2003-04-08 2018-04-03 Dart Neuroscience (Cayman) Ltd. Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
WO2002013867A2 (en) 2000-08-10 2002-02-21 Cold Spring Harbor Laboratory Augmented cognitive training
US7868015B2 (en) 2000-08-10 2011-01-11 Cold Spring Harbor Laboratory Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit
GB0111078D0 (en) 2001-05-04 2001-06-27 Novartis Ag Organic compounds
AR037517A1 (es) 2001-11-05 2004-11-17 Novartis Ag Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria
AR037714A1 (es) 2001-12-06 2004-12-01 Maxia Pharmaceuticals Inc Derivados de tiazolidinona y oxazolidinona 2-sustituidos para la inhibicion de fosfatasas y el tratamiento de cancer
AU2003295656B2 (en) 2002-11-19 2010-11-11 Memory Pharmaceuticals Corporation Pyridine N-oxide compounds as phosphodiesterase 4 inhibitors
GB0229281D0 (en) 2002-12-16 2003-01-22 Novartis Ag Organic compounds
US20050020587A1 (en) 2003-07-25 2005-01-27 Pfizer Inc Nicotinamide derivatives useful as PDE4 inhibitors
MY141255A (en) 2003-12-11 2010-03-31 Memory Pharm Corp Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
KR101267392B1 (ko) * 2004-06-30 2013-05-23 주식회사 씨앤드씨신약연구소 피리딘 유도체 및 그의 제조방법
GB0425572D0 (en) 2004-11-19 2004-12-22 Glaxo Group Ltd 1,7-Naphthyridines
WO2006124874A2 (en) * 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibitors of b-raf kinase
US7829713B2 (en) 2006-02-28 2010-11-09 Helicon Therapeutics, Inc. Therapeutic piperazines
ES2425578T3 (es) 2006-02-28 2013-10-16 Dart Neuroscience (Cayman) Ltd Compuestos terapéuticos
SI1874781T1 (sl) 2006-04-19 2009-12-31 Boehringer Ingelheim Int Dihidrotienopirimidini za zdravljenje vnetnih obolenj
WO2007123953A2 (en) * 2006-04-19 2007-11-01 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
JP5440934B2 (ja) 2006-05-24 2014-03-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換プテリジン
EP2074096B1 (en) * 2006-10-04 2012-06-27 F. Hoffmann-La Roche AG 3-pyridinecarboxamide and 2-pyrazinecarboxamide derivatives as hdl-cholesterol raising agents
JP2010527243A (ja) 2007-05-15 2010-08-12 ヘリコン セラピューティクス,インコーポレイテッド 低分子干渉RNA(siRNA)を用いた記憶形成に関わる遺伝子の同定方法
CN104072489B (zh) 2007-08-27 2017-07-07 达特神经科学(开曼)有限公司 治疗用异噁唑化合物
JP2011504505A (ja) * 2007-11-21 2011-02-10 デコード ジェネティクス イーエイチエフ 肺および心血管障害を治療するためのビアリールpde4抑制剤
US8877816B2 (en) 2007-11-21 2014-11-04 Decode Genetics Ehf 4-(or 5-) substituted catechol derivatives
WO2009067600A2 (en) * 2007-11-21 2009-05-28 Decode Genetics Ehf Biaryl pde4 inhibitors for treating inflammation
CA2722586A1 (en) 2007-11-21 2009-05-28 Decode Genetics Ehf Substituted benzoazole pde4 inhibitors for treating inflammatory, cardiovascular and cns disorders
WO2010003084A2 (en) 2008-07-02 2010-01-07 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
WO2010056195A1 (en) 2008-11-14 2010-05-20 Astrazeneca Ab New compounds 575
WO2010059836A1 (en) 2008-11-20 2010-05-27 Decode Genetics Ehf Substituted aza-bridged bicyclics for cardiovascular and cns disease
JP2013540145A (ja) * 2010-10-21 2013-10-31 ウニベルシテート デス ザールランデス コルチゾール依存性疾患の治療用の選択的cyp11b1阻害剤
SG11201504709PA (en) * 2013-03-14 2015-07-30 Dart Neuroscience Llc Substituted pyridine and pyrazine compounds as pde4 inhibitors

Similar Documents

Publication Publication Date Title
JP2016512259A5 (enExample)
RU2015137615A (ru) Замещенные пиридиновые и пиразиновые соединения в качестве ингибиторов pde4
JP2014528446A5 (enExample)
RU2019118623A (ru) Пирролопиримидины в качестве потенциаторов мвтр
JP2007523182A5 (enExample)
RU2372347C2 (ru) Соединения тетразола и их применение в качестве антагонистов метаботропного рецептора глутамата
JP2017500364A5 (enExample)
DK2491038T3 (da) Disubstituerede octahydropyrrolo [3,4-c]pyrroler som orexin receptormodulatorer
JP2019504854A5 (enExample)
RU2012146246A (ru) Антибактериальные производные изохинолин-3-илмочевины
JP2018524331A5 (enExample)
JP2013508403A5 (enExample)
JP2013518046A5 (enExample)
HRP20220096T1 (hr) Inhibitori lizin specifične demetilaze-1
JP2018535999A5 (enExample)
JP2016519096A5 (enExample)
JP2016514718A5 (enExample)
JP2014531465A5 (enExample)
JP2015514072A5 (enExample)
JP2017502049A5 (enExample)
JP2014518214A5 (enExample)
RU2012133475A (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
JP2015528022A5 (enExample)
SI2763982T1 (en) Substituted benzylindazoles for use as inhibitors of Bub kinase in the treatment of hyperproliferative diseases
JP2014521711A5 (enExample)